Early Detection of Pancreatic Cancer

The Role of Industry in the Development of Biomarkers

Barbara J. Kenner, Vay Liang W. Go, Suresh T Chari, Ann E. Goldberg, Laura J. Rothschild

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9%. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, "Early Detection of Sporadic Pancreatic Cancer Summit Conference," a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, "Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers," which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.

Original languageEnglish (US)
Pages (from-to)1238-1241
Number of pages4
JournalPancreas
Volume46
Issue number10
DOIs
StatePublished - Nov 1 2017

Fingerprint

Pancreatic Neoplasms
Early Detection of Cancer
Industry
Biomarkers
Hope
Survival Rate
Research

Keywords

  • biomarkers
  • early detection
  • high-risk group
  • PDAC
  • screening

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Early Detection of Pancreatic Cancer : The Role of Industry in the Development of Biomarkers. / Kenner, Barbara J.; Go, Vay Liang W.; Chari, Suresh T; Goldberg, Ann E.; Rothschild, Laura J.

In: Pancreas, Vol. 46, No. 10, 01.11.2017, p. 1238-1241.

Research output: Contribution to journalArticle

Kenner, Barbara J. ; Go, Vay Liang W. ; Chari, Suresh T ; Goldberg, Ann E. ; Rothschild, Laura J. / Early Detection of Pancreatic Cancer : The Role of Industry in the Development of Biomarkers. In: Pancreas. 2017 ; Vol. 46, No. 10. pp. 1238-1241.
@article{89376082c333457990f9f2c161e58de7,
title = "Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers",
abstract = "A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9{\%}. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, {"}Early Detection of Sporadic Pancreatic Cancer Summit Conference,{"} a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, {"}Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers,{"} which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.",
keywords = "biomarkers, early detection, high-risk group, PDAC, screening",
author = "Kenner, {Barbara J.} and Go, {Vay Liang W.} and Chari, {Suresh T} and Goldberg, {Ann E.} and Rothschild, {Laura J.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1097/MPA.0000000000000939",
language = "English (US)",
volume = "46",
pages = "1238--1241",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Early Detection of Pancreatic Cancer

T2 - The Role of Industry in the Development of Biomarkers

AU - Kenner, Barbara J.

AU - Go, Vay Liang W.

AU - Chari, Suresh T

AU - Goldberg, Ann E.

AU - Rothschild, Laura J.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9%. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, "Early Detection of Sporadic Pancreatic Cancer Summit Conference," a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, "Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers," which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.

AB - A diagnosis of pancreatic cancer is devastating owing to its poor prognosis, with a 5-year survival rate of only 9%. Currently, most individuals are diagnosed at a late stage when treatment options are limited. Early detection of pancreatic cancer provides the greatest hope for making substantial improvements in survival. The Kenner Family Research Fund in partnership with the American Pancreatic Association has sponsored a series of fora to stimulate discussion and collaboration on early detection of pancreatic cancer. At the first forum in 2014, "Early Detection of Sporadic Pancreatic Cancer Summit Conference," a strategic plan was set forth by an international group of interdisciplinary scientific representatives and subsequently The Strategic Map for Innovation was generated. The current conference report is the third forum in the series, "Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers," which was held in Boston, Massachusetts, on October 27, 2016. This report provides an overview of examples of innovative initiatives by industry and confirms the critical need for collaboration among industry, government, research institutions, and advocacy groups in order to make pancreatic cancer more easily detectable in its earlier stages, when it is more treatable.

KW - biomarkers

KW - early detection

KW - high-risk group

KW - PDAC

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85032196288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032196288&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000939

DO - 10.1097/MPA.0000000000000939

M3 - Article

VL - 46

SP - 1238

EP - 1241

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 10

ER -